Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02314247 · OUTCOME

Progression Free Survival (PFS)

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma · Source last updated 2023-01-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
95% Confidence Interval
Time frame
Study treatment start date to date of disease progression or date of death. Patients without documented PD are censored on date of last radiologic assessment.

What was measured

Duration of time from start of study treatment to date of disease progression or death from any cause.

Analysis population: Intent to Treat population.

Groups in this outcome

Selinexor (PTCL)

Assigned to 60 mg dose, 6 doses/cycle

Selinexor (CTCL)

Assigned to 60 mg dose, 6 doses/cycle (6 patients); assigned to 60 mg dose, 8 doses/cycle (1 patient)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Selinexor (PTCL)9
Selinexor (CTCL)7

Reported measurements

Source class 1
Values in Days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Selinexor (PTCL)111.0Not reported41.0130.0Not reported
Selinexor (CTCL)112.0Not reported85.0225.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        41.0
        upper Limit
        130.0
        value
        111.0
      2. group Id
        OG001
        lower Limit
        85.0
        upper Limit
        225.0
        value
        112.0
denoms
  1. counts
    1. group Id
      OG000
      value
      9
    2. group Id
      OG001
      value
      7
    units
    Participants
description
Duration of time from start of study treatment to date of disease progression or death from any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Assigned to 60 mg dose, 6 doses/cycle
    id
    OG000
    title
    Selinexor (PTCL)
  2. description
    Assigned to 60 mg dose, 6 doses/cycle (6 patients); assigned to 60 mg dose, 8 doses/cycle (1 patient)
    id
    OG001
    title
    Selinexor (CTCL)
param Type
MEDIAN
population Description
Intent to Treat population.
reporting Status
POSTED
time Frame
Study treatment start date to date of disease progression or date of death. Patients without documented PD are censored on date of last radiologic assessment.
title
Progression Free Survival (PFS)
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice